Adriaan Voors


Adriaan Voors is Professor of Cardiology and specializes in heart failure. Since July 2003, Professor Voors works as a Cardiologist in the University Medical Centre Groningen, The Netherlands. In 2007, he became Established Clinical Investigator of the Netherlands Heart Foundation, and in May 2010, he became Professor of Cardiology at the University Medical Center Groningen.

Current activities

Professor Voors is chairing a research group of students, MD-PhD-fellows and post-docs mainly on using –omics data to increase our knowledge on pathophysiology leading to personalized therapies in heart failure. He is an editorial board member of the European Journal of Heart Failure, Clinical Research in Cardiology Cardiovascular Drugs and Therapy, the Journal of Cardiovascular Medicine, and Heart Failure Reviews. He is/was involved as principal investigator/executive/steering committee member of 44 clinical trials on novel therapies in acute and chronic heart failure. Prof. Voors was a member of the 2012 ESC Heart Failure Guidelines Committee, and is the co-chair of the 2016 ESC Heart Failure Guidelines. He has authored more than 500 peer-reviewed papers and several books and chapters and his Hirsch-index is 81.

My projects


Facilitate personalized therapies in patients with heart failure



Personalised Medicine in Chronic Disease Management

My publications

Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease

Chronic kidney disease (CKD), defined by a reduced estimated glomerular filtration rate (eGFR) is a common comorbidity in patients with heart failure with reduced ejection fraction (HFrEF). CKD is a significant risk factor for worse cardiovascular outcomes and is associated with more severe heart failure. Furthermore, when present, CKD often influences the decision to start, uptitrate, or discontinue possible life-saving HFrEF therapies. Historically pivotal HFrEF trials have excluded heart failure patients with CKD stage 4 and 5 (eGFR <30 mL/min/1.73 m2. Therefore, information on the efficacy and safety of HFrEF therapies in these patients is limited. More recent HFrEF trials with novel classes of drugs have included patients with more severe CKD. In this review, we show that for all-cause mortality and the combined endpoint of cardiovascular death or heart failure hospitalization, most HFrEF drug classes are safe and effective up to CKD stage 3B (eGFR minimum 30 mL/min/1.73 m2). In HF patients with CKD stage 4 (eGFR 15 – 29 ml/min/1.73m2), evidence is available of efficacy and tolerability of sodium glucose cotransporter 2 inhibitors, and to a lesser extent in angiotensin-converting enzyme inhibitors, vericiguat, digoxin and omecamtiv mecarbil, regarding the endpoint of cardiovascular death and heart failure hospitalization. In CKD stage 5 (eGFR < 15 mL/min/1.73 m2 or dialysis) data is lacking for both endpoints. After initiation of several HFrEF drug classes (angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/mineralocorticoid receptor antagonists/angiotensin receptor blocker neprilysin inhibitors/sodium glucose cotransporter 2 inhibitors), an initial decline in eGFR is frequently observed. However, renal function often stabilizes over time, and the drugs maintain their efficacy. In the context of a stable or improving clinical condition, a decline in eGFR should therefore not be a cause for concern and should not lead to discontinuation of life-saving HFrEF therapies.

view on PubMed

Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure with Preserved Ejection Fraction

Thomas M Gorter, Gijs van Woerden, Michiel Rienstra, Michael G Dickinson, Yoran M Hummel, Adriaan A Voors, Elke S Hoendermis, Dirk J van Veldhuisen. JACC Heart Fail 2020.

view on PubMed

Sex-specific associations of obesity and N-Terminal Pro-B-Type Natriuretic Peptide levels in the general population

Navin Suthahar, Wouter C Meijers, Jennifer E Ho, Ron T Gansevoort, Adriaan A Voors, Peter van der Meer, Stephan J L Bakker, Stephane Heymans, Vanessa van Empel, Blanche Schroen, Pim van der Harst, Dirk J van Veldhuisen, and Rudolf A de Boer. Eur J Heart Fail. 2018.

view on PubMed

A single dose of erythropoietin in ST-elevation myocardial infarction.

Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH, Tio RA, van 't Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, van Gilst WH, van Veldhuisen DJ; HEBE III Investigators. Eur Heart J. 2010

view on publisher site

Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction.

Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P, Voors AA. J Am Coll Cardiol. 2018

view on publisher site